The therapeutic effect of Salapon® on intestinal dysbiosis, atopic dermatitis and related ailments has been investigated in numerous clinical studies. The research was conducted in several countries and the results are as follows:
1. SALAPON® has a positive effect on intestinal microflora after 14 days of use
Number of patients: 60 children with functional disorders of the gastrointestinal tract: constipation, functional distension, functional abdominal pain and flatulence. (3 – 17 years)
Group 1 – 45 patients; SALAPON®
Group 2 – 15 patients; standard therapy (antispasmodics and probitics)
The results of microbiological analysis have shown that after two weeks of SALAPON® administration in patients in the test group microbiological indices were normalized while patients in the control group preserved elevated level of hemolyzing E. coli and fungi Candida, low levels of bifido and lactobacteria.
Scientific research Institute of Pediatrics and Pediatric Surgery, Moscow (2003)
2. SALAPON® has a positive effect on the symptoms of the disease after 14 days of use
Number of patients: 60 children with functional disorders of the gastrointestinal tract: constipation, functional distension, functional abdominal pain and flatulence. (3 – 17 years)
Group 1 – 45 patients; SALAPON®
Group 2 – 15 patients; standard therapy (antispasmodics and probitics)
After 14 days of SALAPON® therapy, symptoms such as constipation, abdominal pain and flatulence receded in almost 80% of patients, in contrast to standard therapy, which showed significantly less satisfying results.
Scientific research Institute of Pediatrics and Pediatric Surgery, Moscow (2003)
3. SALAPON® may be recommended as initial therapy for patients with mild atopic dermatitis
Number of patients: 89
(18 – 60 years) SCORAD> 25
Group 1 – 44 patients; standard therapy + SALAPON®
Group 2 – 45 patients; standard therapy
(Moscow Clinical Center, State University of Medicine and Dentistry, Department of Dermatology and Venereology; 2009)
*SCORAD (SCORing Atopic Dermatitis index) is a questionnaire used to determine the severity of atopic dermatitis.
4. SALAPON® may be recommended as combination therapy with local therapy in patients with moderately severe atopic dermatitis
Number of patients: 40
(6 months – 3 years)
Group 1 – 22 patients, mild AD, SCORAD 15% – 29%
Group 2 – 18 patients, moderately severe AD, SCORAD up to 59%
(Moscow Children’s Health Science Center, 2009)
*SCORAD (SCORing Atopic Dermatitis index) is a questionnaire used to determine the severity of atopic dermatitis.